Latin America is a conglomerate of adjacent countries that share a Latin extraction and language (Spanish or Portuguese) and exhibit extreme variations in socioeconomic status. End-stage renal disease prevalence and incidence rates have been growing steadily, probably as a result of the increase in life expectancy, aging of the population, a growing epidemic of type 2 diabetes, and a fast epidemiologic transition across the region. Chronic noncommunicable diseases impose an enormous cost, barely supported at present and unlikely afforded by Latin America in the future. National health surveys in Chile, Mexico, and Argentina showed a high prevalence of cardiovascular risk factors. A total of 21% of the Chilean population had a creatinine clearance <80 ml/min. Among the surveyed people, 8.6% of Argentines, 14.2% of Chileans, and 9.2% of Mexicans had proteinuria. There are ongoing national chronic kidney disease detection programs in Brazil, Cuba, Peru, Uruguay, and Venezuela; Argentina, Colombia, Bolivia, Dominican Republic, Guatemala, and Paraguay are still developing them. The prevalence of cardiovascular and renal risk factors is high in Latin America. Data about chronic kidney disease are scarce, but public health awareness is high, evidenced by ongoing or developing chronic kidney disease detection programs. High-risk patients (e.g., those with hypertension or diabetes, elderly) must be studied, using simple determinations such as creatinine and proteinuria. For these programs to succeed, lifestyle changes must be encouraged, and public awareness must be increased through teaching and media-oriented activities.
L
atin America (LA) is a conglomerate of neighboring countries that share a common Latin ancestry and the Spanish or Portuguese language. It includes Central and South American countries, the Caribbean Hispanic Islands, and Mexico. The territory has an area of 21,069,501 km 2 . Brazil, with 8,514,877 km 2 , is the fifth-largest country in the world.
The estimated population is 561,211 million (half of whom live in Brazil and Mexico) (1) . Although largely of white origin, it is an amalgam of ancestries and ethnic groups. The composition varies from country to country. Native Americans comprise 8% of the population but prevail in Bolivia and constitute sizable minorities in Ecuador, Guatemala, and Peru. In Argentina, Uruguay, and Puerto Rico, white people predominate. In the remaining countries there is a high proportion of Mulatto, Native American, mixed-race, and black people, all ethnic groups being highly mixed (2) . The annual population growth is 1.3%, and, according to estimates, it will increase to 661,454 million in 2020 (1) .
The ESRD prevalence has been growing by 6.8% annually during the past 5 yr. The incidence rate increased from 33.3 patients per million people (pmp) in 1993 to 167.8 pmp in 2005 (3) . This increment derives from many concurrent causes:
• Life expectancy at birth increased by 5 yr in the past 15 (from 67 to 72 yr in 2004) (4, 5) , determining a growth in the population older than 65, representing a 6% of LA population in 2005 (1) • A type 2 diabetes epidemic, with a constantly increasing prevalence in most countries of the region • Fast lifestyle changes, associated with the population's moving from rural areas to big cities, which in time promotes sedentary behavior and overweight (currently 78% of the population is urban [1] )
Chronic noncommunicable diseases, including chronic kidney disease (CKD), are the first cause of death in developed countries. They also impose an enormous cost to countries with a small or medium income (6), such as in LA. In many countries in LA, the heavy burden of noncommunicable diseases such as diabetes, cardiovascular diseases, arterial hypertension, and CKD is not sustainable now and will be unlikely afforded in the future. This reality urges us to develop early detection and prevention programs for cardiovascular and renal risk factors as well as to make the early diagnosis of CKD available, with the aim of putting an end to its progression rate. We first describe ESRD treatment in LA and then summarize the present situation of risk factors and preventive policies in the various countries.
of the Latin American Society of Nephrology and Hypertension (SLANH). This registry, in operation since 1991, collects data on ESRD from the 20 SLANH member countries, a currently comprising 97% of the region's population. The data collection methods have been reported elsewhere (2,3). Although not always universal, the data collected over the years have improved our knowledge on renal replacement therapy (RRT) in LA, promoted the organization of new renal registries in the region, and allowed comparisons with other regions in the world and the analysis of regional trends in ESRD epidemiology and its treatment.
As mentioned, the ESRD therapy prevalence has been steadily increasing on a yearly basis, mounting to 478.2 pmp according to the last LADKTR survey (Figure 1 ). On December 31, 2005 , in the 20 SLANH countries, 147,158 patients were undergoing long-term hemodialysis (44% in Brazil), 50,251 were on chronic peritoneal dialysis (65% in Mexico), and Ͼ52,000 were living with a functioning kidney graft (3).
The prevalence rate varies enormously among countries; this is basically associated with the different health coverage and gross national income (GNI). Thus, the prevalence rate is Ͼ600 pmp in Puerto Rico, Chile, Uruguay, and Argentina; between 300 and 600 pmp in Colombia, Brazil, Mexico, Panama, and Venezuela; and significantly smaller in the rest of the countries, as low as Ͻ50 pmp. Figure 2 shows the relation between the prevalence rate and GNI (3) .
A simultaneous rise in the incidence rate, from 33.3 pmp in 1993 to 167.5 pmp in 2005, has occurred. This growth in prevalence and incidence is present in all countries in LA; the only one tending to an incidence rate stabilization is Puerto Rico (310 pmp in 2005).
Diabetes has remained the leading cause of ESRD (30.3% of incident population). The highest incidence is reported in Puerto Rico (65%), Mexico (51%), Venezuela (42%), and Colombia (35%) (3) .
Regarding renal transplantation, active programs are run- 
ESRD Therapy Coverage in LA
LA is a region of deep inequities. This can be easily esteemed when different socioeconomic indexes are analyzed. For example, LA's mean GNI is US $4045, but it ranges between $910 in Nicaragua and $10,560 in Puerto Rico; the life expectancy at birth ranges from 64.5 yr in Bolivia to 78.7 yr in Costa Rica (average of 72 yr); the human development index (a composite index that measures a country's average achievements on the basis of life expectancy, literacy, education, and standard of living) varies from 0.663 in Guatemala to 0.863 in Argentina with an average of 0.797 for LA (5-7). The imbalance is also present in the access to ESRD therapy. Coverage of 100% of patients who receive a diagnosis of ESRD is available in Argentina, Brazil, Chile, Cuba, Puerto Rico, Uruguay, and Venezuela. In the remaining countries, the coverage percentage varies from 56% in Colombia to only 25% in Peru and Paraguay (3) .
Predictably, in the countries with 100% coverage, prevalence rates are higher, with a mean of 553 pmp for dialysis therapy and 18.2 pmp for kidney transplants; however, when the remaining countries are analyzed, prevalence rates in the population with health insurance are as high as or even higher than those observed in nations with full coverage. For instance, in 2000, the ESRD therapy prevalence rate in Mexico was 376 pmp, but among the population covered by the Health Security System in Jalisco State, it was 939 pmp (8) . In Peru, the country's prevalence rate was 196 pmp but increased to 789 pmp in the insured group in 2003 (9) . These data confirm that LA's ESRD prevalence is not lower than that in developed regions worldwide. The lower RRT prevalence probably reflects an underdiagnosis of the disease, even in countries with full ESRD treatment coverage.
Prevalence of CKD Progression Risk Factors in LA
This information regarding prevalence of CKD progression risk factors is scarce, even nonexistent in several countries; in addition, the available studies about prevalence of cardiovascular and renal disease risk factors are insufficient and have not always been performed with the same methods. Moreover, during the past few years, LA has been experiencing a fast epidemiologic transition (characterized by a long-term shift in mortality and disease patterns whereby infection pandemics are replaced by chronic noncommunicable diseases) (10), which a Countries grouped in SLANH are Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Ecuador, Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, and Venezuela. nowadays is going through different phases in different countries. All these facts make it difficult to establish the real prevalence of CKD progression risk factors.
To develop public health policies and programs, we need to know the prevalence and distribution of risk factors in the population, as well as the trends that are developing in different groups. Thus, national health surveys are highly desirable; however, most of the countries in LA conduct them only sporadically, mainly focusing on infections and on child and mother mortality. Argentina, Chile, and Mexico recently finished national health surveys, which have revealed a high prevalence of risk factors (Table 1) . Some facts are prominent and emphasize the magnitude of the epidemiologic change, such as the tobacco-smoking habit increasing in teenagers; the increment in obesity and central obesity affecting all age groups, including children and teenagers, and prevailing in women; the same incidence of risk factors in rural and urban population; and the increase of metabolic syndrome (reaching 48% among people older than 65 yr in the Chilean survey) (11) (12) (13) .
In Uruguay, the prevalence of hypertension ranges between 33 and 39% (14 -17) , and the prevalence of diabetes was 8% in a survey of adults for whom a fasting serum glucose was conducted (18) . Although there has been an established RRT program for all ESRD-diagnosed patients since 1981, there has been no study on the prevalence of CKD. With the aim of finding out about the prevalence of cardiovascular and renal disease risk factors, a national survey will begin in 2008.
In Brazil, several population-based studies found a high prevalence of cardiovascular risk factors (Table 2) (19 -26) . The prevalence of hypertension was directly correlated to age, overweight/obesity, abdominal obesity, diabetes, alcohol consumption, and relatives with hypertension (20 -26) .
The Brazilian Society of Cardiology conducted a nationwide survey of cardiovascular risk factors: 2500 people filled out a questionnaire with lifestyle information, and 1500 consented to a physical examination and blood testing. This survey showed also a high prevalence of risk factors (Table 2) . Unfortunately, results about increased creatinine have not been published yet, although they will be available in the future, because serum samples were kept for future determinations (29) . In Peru, a cross-sectional survey that included 14,256 adults showed a 23.7% prevalence of hypertension, with no difference between people living 3000 m above or below sea level (30) . Clearly, there is a high prevalence of cardiovascular and renal risk factors in LA: hypertension, diabetes, and obesity, among others. Their prevention and treatment may strongly contribute to diminish cardiovascular mortality and ESRD progression.
What we do not have are data concerning the prevalence of CKD in LA or about who will progress to ESRD. So far, the Mexican and Chilean health surveys are the only ones providing national data; small studies performed in Brazilian and Argentine cities supply some more partial data. In the 2000 Mexican Health Survey, 9.2% of participants had proteinuria, which was strongly associated with hypertension, diabetes, obesity, and age (31) . The Chilean survey found 14.2% prevalence of proteinuria and 21% with a creatinine clearance (Ccr) Ͻ80 ml/min (12).
The first LA population-based study to detect the prevalence of elevated serum creatinine was conducted in 1997 in Bambuí, Figure 2 . Linear correlation between gross national income (GNI; per capita in US dollars) (7) and prevalence of renal replacement therapy in 2005 (all modalities). a small Brazilian town. Only 0.5% of the adults (18 to 59 yr of age) and 5.1% of the senior citizens (Ͼ60 yr of age) were found to have high creatinine (Ͼ1.3 mg/dl for men and 1.1 mg/dl for women). These figures may be underestimated, however, because they may be the result of a lower survival of patients with renal dysfunction, related to a lack of medical attention, or to a selective migration of those with a more advanced disease to larger cities looking for available, complex medical procedures (32) . In Argentina, screening programs in adults from several regions showed an 8.3 to 8.6% prevalence of proteinuria (which exceeded 14% in people older than 60) and 4.1% prevalence of microalbuminuria (33) (34) (35) .
In Mexico, a population-based cross-sectional survey in the city of Morelia was conducted on a sample of 3961 adults.
Extrapolating the results to the whole country, the prevalence of Ccr Ͻ60 ml/min was 80,788 pmp and Ͻ15 ml/min was 1142 pmp, similar to those found in industrialized countries. Hypertension was present in 25% of the patients with a Ccr Ͻ60 ml/min and in 58% of those with a Ccr Ͻ15 ml/min. Proteinuria was detectable in 8.7% of those with Ccr Ͻ60 ml/min but increased to 12.5% in those with diabetes and hypertension (36) . If we extrapolate the values published in the Third National Health and Nutrition Examination Survey (NHANES III) (37) for the population of LA in comparable age groups, there may be 47,000,000 patients with CKD in the region (Table 3 ). These figures might not be valid in LA, but we have shown that renal disease risk factor prevalence is high in countries in LA, and the use of this extrapolation may constitute a powerful tool to increase public health awareness about the burden of renal and cardiovascular disease and to point out the need to obtain data in each country. Meanwhile, the establishment of programs meant to detect early patients who are at risk for developing CKD and prevent its progression is of the utmost importance; however, a detection program cannot be based on screening the whole population. We need simple programs directed to highrisk groups, such as the elderly; those with diabetes, hypertension, and obesity; and relatives of patients with ESRD. These programs may include simple actions, such as BP control, microalbuminuria or proteinuria and creatinine measurements (using simple formulas to calculate GFR), and glycemic control in patients with diabetics and metabolic syndrome. Besides performing an adequate diagnosis and treatment, we must train primary care physicians, and the population must be alerted about their probable belonging to groups at risk for having CKD so that detection can be made earlier to facilitate consultations and follow-up by specialized health teams. It is also necessary to load the information in a database in a way that will let us identify patients at highest risk for adverse outcomes and with a higher lifetime risk for ESRD, as well as the prevalence of such individuals in target groups. We know that lower income, diabetes, hypertension, hematuria, proteinuria, and an elevated serum creatinine all are independent ESRD risk factors in the general community. Other variables, such as a family history of CKD, may also be useful for risk stratification. The combination of an elevated creatinine and proteinuria may be particularly useful in identifying a group at higher risk for progression. The use of these measurements in target groups sorted by older age, diabetes, and hypertension increases the probability of finding abnormalities through screening and improves the screening effectiveness itself.
Status of Detection Programs in LA
This year, the LADKTR Committee collected data in a simple survey, designed with the intention of finding out both whether the prevalence of risk factors was known in each country and whether national health policies for CKD detection and prevention existed. The survey, answered by 14 countries, showed that there is public health awareness about the burden of CKD, as revealed by the implementation or development of national CKD detection programs in 11 of the 14 surveyed countries. In 11, cardiovascular disease risk factors prevalence is already known, although the data are frequently partial. Smoking is forbidden in public places in most of the countries (Table 4) . Moreover, partially supported by the International Society of Nephrology, there are ongoing screening and prevention programs in La Paz (Bolivia) and Isle of Youth (Cuba). Projects in Guadalajara (Mexico), Guayaquil (Ecuador), Tarija/La Paz (Bolivia), and Uruguay are about to start. As a result, a lot of information will be available in the next few years.
During the past decade, the SLANH has been developing multiple activities to improve CKD detection and renal health in the region. In 2005, a consensus emerged, establishing that it is time to collect data, to recognize and evaluate risk factors, to implement primary prevention policies, to reduce the shortage of physicians and nurses, to implement educational programs on CKD, to promote public awareness programs on CKD, and to standardize GFR measurements (38) .
Conclusions
Although scarce, available data seem to confirm that the prevalence of cardiovascular and renal risk factors is high in LA. Data about CKD prevalence are even more limited, although the prevalence of proteinuria seems to be high (Ͼ8% whenever tested). Some national and several small population survey studies have been done or are ongoing in various cities or regions in LA; their results are available or will be in the near future.
There is public health awareness regarding CKD detection, as shown by the implementation or development of national CKD detection programs in 11 countries. These programs must focus their attention on high-risk patients, such as those with hypertension, diabetes, and obesity, and include simple actions, such as BP and glucose control and microalbuminuria or proteinuria and serum creatinine measurements. For them to succeed, we need to reach primary care physicians and the general population through teaching and media-oriented activities to improve awareness at all levels, a task in which nephrologists must be heavily involved. Finally, the patients who receive a diagnosis of CKD and their follow-up must be included in a database, to identify those who are at risk for the worst outcomes.
